Clinical trials in Clermont Ferrand – page 6

655 clinical trials in Clermont Ferrand, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Clermont Ferrand at a glance

655

clinical trials

Research sites3

Quick filters

655 trials in Clermont Ferrand

Open in trial search

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Post lumbar puncture syndrome

Recruiting

Comparing Sphenopalatine Block Using Lidocaine and Prilocaine to Blood Patch for Patients with Post-Dural Puncture Syndrome

Registered drugNo placebo

Comparing Sphenopalatine Block Using Lidocaine and Prilocaine to Blood Patch for Patients with Post-Dural Puncture Syndrome

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lidocaine
Sponsor:University Hospital Of Clermont-Ferrand

Contact Research Centre

Cutaneous lupus erythematosus

Recruiting

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenalidomide
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Datopotamab Deruxtecan
Sponsor:AstraZeneca AB

Contact Research Centre

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sacituzumab Govitecan
Sponsor:Unicancer

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Osteoarthritis

Recruiting

Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

Registered drug

Study of Methotrexate Treatment for Patients with Erosive Hand Osteoarthritis Not Responding to Standard Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Folic Acid
Sponsor:Centre Hospitalier Universitaire De Nice

Contact Research Centre

Bronchiolitis+1

Recruiting

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

Study of nirsevimab and RSV vaccine (Abrysvo) for prevention of respiratory syncytial virus infection in infants during their first year of life

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Nirsevimab
Sponsor:Centre Hospitalier Annecy Genevois

Contact Research Centre

Colorectal adenocarcinoma

Recruiting

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Association Gercor

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Clermont Ferrand

What the registry says about research in the country

01 Gastrointestinal Research

Innovative studies focusing on inflammatory bowel diseases including groundbreaking trials examining fecal microbiota transplantation in both Crohn's disease and ulcerative colitis. Research aims to evaluate new therapeutic approaches for patients with moderate to severe conditions.

Crohn's Disease Management
Ulcerative Colitis Treatment
Microbiota-based Therapies

These trials are exploring alternative treatment pathways for patients who have not responded to conventional therapies.

02 Oncology Studies

Comprehensive research in multiple myeloma and various cancer types, including innovative treatments for esophageal squamous cell carcinoma and pleural mesothelioma. Studies evaluate new therapeutic combinations and maintenance strategies.

Blood Cancer Treatments
Prostate Cancer Therapy
Biliary Tract Cancer Research

Focus on improving patient outcomes through targeted therapies and immunological approaches.

03 Autoimmune Conditions

Advanced research into rheumatoid arthritis and multiple sclerosis, investigating optimized treatment protocols and maintenance therapies. Studies aim to improve long-term disease management and patient quality of life.

Multiple Sclerosis Treatments
Rituximab Optimization
Antibody-based Therapies

Emphasis on developing more effective and tolerable treatment regimens.

Back to France All countries